SCHEMBL911603

SCHEMBL911603

Cc1ccsc1C.OBO

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
PKM P14618 1/20 0.38
ATM Q13315 1/20 0.38
GSK3B P49841 1/20 0.38
ALDH1A1 P00352 3/20 0.35
CYP2A6 P11509 4/20 0.34
POLB P06746 2/20 0.34
NISCH Q9Y2I1 1/20 0.34
GAA P10253 3/20 0.33
HPGD P15428 3/20 0.33
HSD17B10 Q99714 2/20 0.33
ALOX5 P09917 2/20 0.33
HTT P42858 2/20 0.33
KDM4E B2RXH2 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL113923 0.89
SCHEMBL10584362 0.75 NPC1 (0.35) L3MBTL1NPC1RAB9APKMATM
SCHEMBL20183982 0.75 ALDH1A1 (0.42) L3MBTL1NPC1RAB9APKMATM
Formamide SCHEMBL11400245 0.75 NPC1 (0.40) L3MBTL1NPC1RAB9APKMATM
Glycolic Acid SCHEMBL11539039 0.75 GSK3B (0.44) NPC1RAB9APKMGSK3BALDH1A1
SCHEMBL752807 0.68 ACHE (0.45) L3MBTL1NPC1RAB9APKMALDH1A1
SCHEMBL2961814 0.67
SCHEMBL2975411 0.67
SCHEMBL43816 0.67
SCHEMBL764849 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921299-B2 Detergents having acceptable color THE PROCTER & GAMBLE COMPANY (US) 2014-12-30 US claimed
US-20260110139-A1 CROSS-LINKED POLYVINYL ALCOHOL ADHESIVES PROCTER & GAMBLE (US) 2026-04-23 US disclosed
US-20260109131-A1 CROSS-LINKED POLYVINYL ALCOHOL ADHESIVES PROCTER & GAMBLE (US) 2026-04-23 US disclosed
US-12522813-B2 Mannanase for formulations having pH 5-12 BASF SE (DE) 2026-01-13 US disclosed
EP-4638687-A2 DETERGENT COMPOSITION COMPRISING CATALASE AND AMYLASE Novozymes A/S (DK) 2025-10-29 EP disclosed
EP-4634219-A1 HIGH STRENGTH LIQUID PROTEASE FORMULATIONS Novozymes A/S (DK) 2025-10-22 EP disclosed
US-20250295120-A1 CLEANING METHOD, USE OF ENZYMES AND CLEANING COMPOSITION NOVOZYMES A/S (DK) 2025-09-25 US disclosed
US-20250129307-A1 Microencapsulation Using Amino Sugar Oligomers NOVOZYMES A/S (DK) 2025-04-24 US disclosed
US-20250084346-A1 ENCAPSULATED SOLID ENZYME PRODUCT NOVOZYMES A/S (DK) 2025-03-13 US disclosed
EP-4466364-A1 CLEANING METHOD, USE OF ENZYMES AND CLEANING COMPOSITION Novozymes A/S (DK) 2024-11-27 EP disclosed
US-20110005003-A1 CATALYTIC LAUNDRY DETERGENT COMPOSITION COMPRISING RELATIVELY LOW LEVELS OF WATER-SOLUBLE ELECTROLYTE THE PROCTER & GAMBLE COMPANY (US) 2011-01-13 US disclosed
EP-2252682-A1 CLEANING COMPOSITIONS The Procter & Gamble Company (US) 2010-11-24 EP disclosed
US-20100120649-A1 Stable Enzyme Solutions and Method of Manufacturing NOVOZYMES A/S (DK) 2010-05-13 US disclosed
EP-2139979-A1 STABLE ENZYME SOLUTIONS AND METHOD OF MANUFACTURING Novozymes A/S (DK) 2010-01-06 EP disclosed
US-20090209447-A1 CLEANING COMPOSITIONS THE PROCTER & GAMBLE COMPANY 2009-08-20 US disclosed
WO-2009102854-A1 CLEANING COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2009-08-20 WO disclosed
WO-2008116915-A1 STABLE ENZYME SOLUTIONS AND METHOD OF MANUFACTURING NOVOZYMES A/S (DK) 2008-10-02 WO disclosed
EP-1924677-A1 STABILIZATION OF CONCENTRATED LIQUID ENZYME ADDITIVES Novozymes A/S (DK) 2008-05-28 EP disclosed
US-20070060493-A1 Stabilization of concentrated liquid enzyme additives NOVOZYMES A/S (DK) 2007-03-15 US disclosed
WO-2007025549-A1 STABILIZATION OF CONCENTRATED LIQUID ENZYME ADDITIVES NOVOZYMES A/S (DK) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250295120-A1 CLEANING METHOD, USE OF ENZYMES AND CLEANING COMPOSITION DNASE1, HEXD, HEXA L3MBTL1 4594/4885NPC1 3916/4885RAB9A 3773/4885
US-20260109131-A1 CROSS-LINKED POLYVINYL ALCOHOL ADHESIVES VCAM1, PLOD3, TLN1 L3MBTL1 1337/4885NPC1 3544/4885RAB9A 2914/4885
US-20260110139-A1 CROSS-LINKED POLYVINYL ALCOHOL ADHESIVES VCL, PLOD3, ILK L3MBTL1 1181/4885NPC1 3812/4885RAB9A 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.